Difference between revisions of "Part:BBa K5036027"

Latest revision as of 13:14, 2 October 2024

dCas9(C)_NLS-Syn-VEGFR-1(VEGF-R1, C-TEV, NLS, TCS(Q,G),HA,dCas9(C), VP64, GAL4, GFP)

Part Description

In our first receptor chain, we've engineered a system that responds to tissue injury. An external domain, VEGF-R1, is attached to an internal domain composed of C terminal domain of TEV protease, a nuclear localization signal (NLS), a TEV cleavage site(TCS(Q,G)), and dCas9(C) which is linked to transcription activators: VP64 and GAL4

Usage

this is our receptor's first chain. our receptor is activated after binding of VEGF to the external domain which is designed to attach specifically to it. after activation the two domains of TEV dimerizes forming catalytically active TEV protease which will cleave the two chains at TCS. upon cleavage of the two chains the two domains of dCas9 dimerize and is released attached to transcription activator to be guided to its direction

This figure illustrates our receptor's first chain structure which contain VP64 and GAL4 as our transcription factor activators.

Dry lab Characterization

we had the chance to match the external domains with different internal domain components to select single suitable receptor chain. The whole chain affinity is affected by the internal domain, thus we had to try VEGFR1Cdcas with VEGFA:

VEGFR1Cdcas-VEGFA binding stability

The interaction between the chain composed of VEGFR1 as an external domain and Cdcas9 as an internal domain with VEGFA yields ΔG of -11.2 kcal mol-1 .

Then we have made a comparison between the four receptor chain variants’ binding stability with VEGFA.

This figure shows that VEGFR2Cdcas-VEGFA complex has the highest stability among other variants and VEGFR1NdCas9-VEGFA complex has the lowest stability among other variants .

The final form of our receptor is composed of two chains, each chain is built of internal and external domains, so we validated these interactions by calculating the binding affinity between the two chains and VEGFA, which simulate the final design of our receptor.

(VEGFR1-Cdcas9 – VEGFR1-Ndcas9) with VEGFA binding stability

The figure displays the interaction between two receptor chains and VEGFA, The (VEGFR1-Cdcas9) chain appears in the red colour, and the (VEGFR1-Ndcas9) chain appears in the blue colour. The VEGFA is in green colour. The calculated binding stability (ΔG) of the combination is -12.9 kcal mol-1 .

The final form of our receptor is composed of two chains, each chain is built of internal and external domains, so we validated these interactions by calculating the binding affinity between the two chains and VEGFA, which simulate the final design of our receptor.

(VEGFR1-Cdcas9 – VEGFR2-Ndcas9) with VEGFA binding stability

The figure displays the interaction between two receptor chains and VEGFA, The (VEGFR1-Cdcas9) chain appears in the red colour, and the (VEGFR2-Ndcas9) chain appears in the blue colour. The VEGFA is in green colour. The calculated binding stability (ΔG) of the combination is -13.7 kcal mol-1 .

The receptor chains’ affinity could be affected by the internal domains interactions with the external domains, so we compared between the receptors’ variants to choose the best receptor design in our project.

The figure shows that the combination of VEGFR1-Cdcas9 and VEGFR2-Ndcas9 took the upper hand among other variants .

Characterization by Mathematical Modeling

The model provides the interaction kinetics of VEGFR1 external domain upon binding of VEGF to it , the result shows satisfactory binding state and stability based on parametric values from literature.

Graph (1). illustrates the decreasing of VEGFR2 (Red line) upon binding of VEGF (A) to form VEGF-VEGFR2 complex (R2A) (Yellow line) which increases till its binding to VEGFR1 (R1), so (R1) also decreases after will ( Black line). To finally form a binding state for fitted ligand receptor complex (R2AR1) (Blue line) .

The continuation of the first model provides the activation kinetics of the TEV protease which occurs subsequent to the binding of VEGF to our receptor allowing the dimerization process for our receptor chains to take place. The result shows sufficient TEV protease activation based on parametric values from literature

Graph (2). Illustrates the dimerization level (Blue line) that reaches steady state upon binding of VEGF to its receptor to activate TEV protease (Red line), The activation level of TEV protease reaches (14) to release d-Cas9 system .

The continuation of the second model provides the activation kinetics of the d-Cas9 system which occurs subsequent to cleavage activity of TEV protease after its activation. The result shows increase in d-Cas9 activity which implies successful cleavage of the TEV protease for releasing the N and C terminal of the d-Cas9 system and its assembly based on parametric values from literature

Graph(2). Illustrates the released d-Cas9 system that activation reaches (240), upon activation of TEV protease.

The continuation of the third model provides the activation kinetics of VP64 transcription activator which occurs subsequent to releasing of the d-Cas9 system to initiate the transcription of the YAP-1.The result shows increase in the transcription level of YAP-1 which implies successful VP64 activation based on parametric values from literature

Graph(1). Illustrates the relation between activation level of VP64 transcription activator (Yellow line) for increasing the transcription level of YAP-1 (Black line).

The continuation of the fourth model provides the activation kinetics of GAL4 transcription activator which occurs subsequent to releasing of the d-Cas9 system to initiate the transcription of the YAP-1.The result shows increase in the transcription level of YAP-1 which implies successful GAL4 activation based on parametric values from literature

Graph (5). Illustrates the relation between activation level of GAL4 transcription activator (Red line) for increasing the transcription level of YAP-1 (Black line).

Experimental Characterization

N-TEV and C-TEV segments Was connected to NES-dCas9(N) and NLS-dCas9(C)VP64, respectively, using a flexible link . To find the best dCas9-synVEGFR structure, TEV(N)-NES-dCas9(N) and TEV(C)-NLS-dCas9(C)VP64 was joined to the VEGFR1(FLT1) and VEGFR2(KDR) ectodomains . These combinations were tested in HEK293T cells and the activity of each homo- and hetero-dimer was measured with and without transgenically expressed VEGFA121

(Baeumler, T.A., Ahmed, A.A. and Fulga, T.A., 2017. Engineering synthetic signaling pathways with programmable dCas9-based chimeric receptors. Cell reports, 20(11), pp.2639-2653.)

The graph demonstrates that the EYFP reporter, a marker of activation score, was significantly upregulated when a C-terminal dCas9 was fused to VEGFR-1 and an N-terminal dCas9 was fused to VEGFR-2 were employed in combination. This effect was particularly pronounced in the presence of VEGFA121 outperforming other dCas9-VEGFR constructs. In addition to this, the combination of VEGFR2: TEV(N)-NES-dCas9(N)/VEGFR1: TEV(C)-NLS-dCas9(C)VP64 heterodimer shows very low activation score in absence of VEGFA121 .

It was hypothesized that by fine-tuning the TCS modules, the assembly of dCas9-VP64 could be controlled so that it only occurs upon simultaneous activation of VEGFR1 and VEGFR2. To investigate this, a set of dCas9(N)-synVEGFR2 and dCas9(C)-synVEGFR1 variants with TCS sequences that had been engineered to weaken their interaction with TEV were designed.Then These combinations were tested in HEK293T cells and the activity of different dCas9-VEGFR variants with TCS sequences was measured with and without transgenically expressed VEGFA121

(Baeumler, T.A., Ahmed, A.A. and Fulga, T.A., 2017. Engineering synthetic signaling pathways with programmable dCas9-based chimeric receptors. Cell reports, 20(11), pp.2639-2653.)

Among the tested dCas9-VEGFR constructs, a combination of dCas9-VEGFR2 with a low-affinity TCS(QL) and dCas9-VEGFR1 with a high-affinity TCS(QG) exhibited relatively low basal activity in absence of VEGFA 121 while preserving high activation score in comparison to other constructs in presence of VEGFA 121. In other words, the previous combination shows the most specific activation of the EYFP reporter in response to VEGFA 121 .

A HEK293 cell line was engineered to express the VEGFR2: TEV(N)-NES-dCas9(N)/VEGFR1: TEV(C)-NLS-dCas9(C)VP64 heterodimer. To assess the effectiveness of the system, flow cytometry was used to compare EYFP reporter expression in cells transfected with either a control sgRNA or one targeting EYFP.

(Baeumler, T.A., Ahmed, A.A. and Fulga, T.A., 2017. Engineering synthetic signaling pathways with programmable dCas9-based chimeric receptors. Cell reports, 20(11), pp.2639-2653.)

Flow cytometry analysis of cells expressing dCas9-VEGFR constructs with either a control sgRNA (sgSCR) or a targeting sgRNA (sgEYFP) revealed that the receptor configuration treated with the targeting sgRNA was unresponsive to activation without VEGFA121 but exhibited a strong response to VEGFA121, with up to a 1,000-fold increase in EYFP activation .

dCas9-VP64-GAL4 expression vector and a UAS-CMV trans-enhancer were constructed to investigate the effectiveness of the GAL4-UAS system for CRISPR-assisted trans-enhancer activation . Both linear (LUAS-CMV) and circular (CUAS-CMV) forms of the UAS-CMV enhancer were successfully recruited to target genes by the dCas9-VP64-fused GAL4 protein.When co-transfected with a reporter gene in 293T cells, both LUAS-CMV and CUAS-CMV significantly activated gene expression on opposite of control conditions.

(Xu X, Gao J, Dai W, Wang D, Wu J, Wang J. Gene activation by a CRISPR-assisted trans enhancer. Elife. 2019 Apr 11;8:e45973. doi: 10.7554/eLife.45973. PMID: 30973327; PMCID: PMC6478495.)

This figure show Flow cytometry analysis of ZsGreen expression shows very high gene expression with (dCas9-VP64-GAL4/sgRNA-LUAS-CMV) and (dCas9-VP64-GAL4/sgRNA- CUAS-CMV) .

This figure shows graphic illustration of flow cytometry analysis of 293 T cells which shows high gene expression with both LUAS-CMV and CUAS-CMV. These findings highlight the potential of the GAL4-UAS system for efficient CRISPR-mediated trans-enhancer activation .

Also these vectors ( dCas9-VP64-GAL4 with linear (LUAS-CMV) and circular (CUAS-CMV) CMV enhancer) were constructed and co-transfected with a reporter gene(HNF4α gene) in HepG2 cells . then results were illustrated and compared with the results of the same construcrts in 293T cells.

(Xu X, Gao J, Dai W, Wang D, Wu J, Wang J. Gene activation by a CRISPR-assisted trans enhancer. Elife. 2019 Apr 11;8:e45973. doi: 10.7554/eLife.45973. PMID: 30973327; PMCID: PMC6478495.)

This figure shows graphic illustration of flow cytometry analysis of 293 T cells and HepG2 cells which shows high gene expression with (dCas9-VP64-GAL4/sgRNA-LUAS-CMV) and (dCas9-VP64-GAL4/sgRNA- CUAS-CMV). Gene expression was higher in HepG2 cells. These findings highlight the potential of the GAL4-UAS system for efficient CRISPR-mediated trans-enhancer activation .

We have done DNA gel electrophoresis to validate the cloning of GFP and gRNA into dCas9(C)_NLS-Syn-VEGFR-1

This figure illustrates the amplified fragments of our inserts GFP within P1 and gRNA shown in p5. .

The final ligated form of plasmid dCas9(C)_NLS-Syn-VEGFR-1 was transformed into competent BL 21

This figure illustrates transformation of dCas9(C)_NLS-Syn-VEGFR-1 and dCas9(N)_NES-Syn-VEGFR-2 plasmids to BL21 competent cells .

Reference

White C, Rottschäfer V, Bridge LJ. Insights into the dynamics of ligand-induced dimerisation via mathematical modelling and analysis. J Theor Biol. 2022 Apr 7;538:110996. doi: 10.1016/j.jtbi.2021.110996. Epub 2022 Jan 24. PMID: 35085533.

Mac Gabhann F, Popel AS. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys Chem. 2007 Jul;128(2-3):125-39. doi: 10.1016/j.bpc.2007.03.010. Epub 2007 Mar 24. PMID: 17442480; PMCID: PMC2711879.

Paththamperuma C, Page RC. Fluorescence dequenching assay for the activity of TEV protease. Anal Biochem. 2022 Dec 15;659:114954. doi: 10.1016/j.ab.2022.114954. Epub 2022 Oct 18. PMID: 36265691; PMCID: PMC9662696.

Morita S, Horii T, Kimura M, Hatada I. Synergistic Upregulation of Target Genes by TET1 and VP64 in the dCas9-SunTag Platform. Int J Mol Sci. 2020 Feb 25;21(5):1574. doi: 10.3390/ijms21051574. PMID: 32106616; PMCID: PMC7084704.

Sequence and Features

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
INCOMPATIBLE WITH RFC[12]
Illegal NheI site found at 2173
21
INCOMPATIBLE WITH RFC[21]
Illegal XhoI site found at 6308
23
COMPATIBLE WITH RFC[23]
25
INCOMPATIBLE WITH RFC[25]
Illegal NgoMIV site found at 3973
Illegal NgoMIV site found at 4046
Illegal NgoMIV site found at 4531
Illegal NgoMIV site found at 5440
1000
INCOMPATIBLE WITH RFC[1000]
Illegal BsaI site found at 6227
Illegal BsaI.rc site found at 7175
Illegal SapI.rc site found at 3268

@@ Line 25: / Line 25: @@
 we had the chance  to match the external domains with different internal domain components to select single suitable receptor chain. The whole chain affinity is affected by the internal domain, thus we had to try VEGFR1Cdcas with VEGFA:
-VEGFR1Cdcas-VEGFA
+VEGFR1Cdcas-VEGFA binding stability
 <html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
 							width:75%;
@@ Line 61: / Line 61: @@
 The final form of our receptor is composed of two chains, each chain is built of internal and external domains, so we validated these interactions by calculating the binding affinity between the two chains and VEGFA, which simulate the final design of our receptor.
-(VEGFR1-Cdcas9 – VEGFR1-Ndcas9) with VEGFA
+(VEGFR1-Cdcas9 – VEGFR1-Ndcas9) with VEGFA binding stability
 <html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
 							width:75%;
@@ Line 79: / Line 79: @@
 The final form of our receptor is composed of two chains, each chain is built of internal and external domains, so we validated these interactions by calculating the binding affinity between the two chains and VEGFA, which simulate the final design of our receptor.
-(VEGFR1-Cdcas9 – VEGFR2-Ndcas9) with VEGFA
+(VEGFR1-Cdcas9 – VEGFR2-Ndcas9) with VEGFA binding stability
 <html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
 							width:75%;
@@ Line 112: / Line 112: @@
 ==Characterization by Mathematical Modeling==
-The model provides the interaction kinetics of VEGFR1 external domain upon binding of VEGF to it , the result shows satisfactory binding affinity and stability based on parametric values from literature.
+The model provides the interaction kinetics of VEGFR1 external domain upon binding of VEGF to it , the result shows satisfactory binding state and stability based on parametric values from literature.
 <html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
 							width:75%;
@@ Line 126: / Line 126: @@
 <p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
-Graph (1). illustrates the decreasing of VEGFR2 (Red line) upon binding of VEGF (A) to form VEGF-VEGFR2 complex (R2A) (Yellow line) which increases till its binding to VEGFR1 (R1), so (R1) also decreases after will ( Black line). To finally form a fitted ligand receptor complex (R2AR1) (Blue line)
+Graph (1). illustrates the decreasing of VEGFR2 (Red line) upon binding of VEGF (A) to form VEGF-VEGFR2 complex (R2A) (Yellow line) which increases till its binding to VEGFR1 (R1), so (R1) also decreases after will ( Black line). To finally form a binding state for fitted ligand receptor complex (R2AR1) (Blue line)
 .   </span></p></div></html>
@@ Line 144: / Line 144: @@
 <p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
-Graph (2). Illustrates the dimerization level (Blue line) that reaches (16) upon binding of VEGF to its receptor to activate TEV protease (Red line), The activation level of TEV protease reaches (14) to release d-Cas9 system
+Graph (2). Illustrates the dimerization level (Blue line) that reaches steady state upon binding of VEGF to its receptor to activate TEV protease (Red line), The activation level of TEV protease reaches (14) to release d-Cas9 system
 .   </span></p></div></html>
@@ Line 163: / Line 163: @@
 <p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
-Graph(2). Illustrates the released d-Cas9 system that activation reaches (220), upon activation of TEV protease.   </span></p></div></html>
+Graph(2). Illustrates the released d-Cas9 system that activation reaches (240), upon activation of TEV protease.   </span></p></div></html>
-The continuation of the third model provides the activation kinetics of VP64 transcription activator which occurs subsequent to releasing of the d-Cas9 system to initiate the transcription of the YAP-1.The result shows increase in transcription activation level of YAP-1 which implies successful VP64 activation based on parametric values from literature
+The continuation of the third model provides the activation kinetics of VP64 transcription activator which occurs subsequent to releasing of the d-Cas9 system to initiate the transcription of the YAP-1.The result shows increase in the transcription level of YAP-1 which implies successful VP64 activation based on parametric values from literature
 <html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
 							width:75%;
@@ Line 185: / Line 185: @@
- The continuation of the fourth model provides the activation kinetics of GAL4 transcription activator which occurs subsequent to releasing of the d-Cas9 system to initiate the transcription of the YAP-1.The result shows increase in transcription activation level of YAP-1 which implies successful GAL4 activation based on parametric values from literature
+The continuation of the fourth model provides the activation kinetics of GAL4 transcription activator which occurs subsequent to releasing of the d-Cas9 system to initiate the transcription of the YAP-1.The result shows increase in the transcription level of YAP-1 which implies successful GAL4 activation based on parametric values from literature
 <html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
 							width:75%;
@@ Line 201: / Line 201: @@
 Graph (5). Illustrates the relation between activation level of GAL4 transcription activator (Red line) for increasing the transcription level of YAP-1 (Black line).
 </span></p></div></html>
+==Experimental Characterization==
+N-TEV and C-TEV segments Was connected to NES-dCas9(N) and NLS-dCas9(C)VP64, respectively, using a flexible link . To find the best dCas9-synVEGFR structure, TEV(N)-NES-dCas9(N) and TEV(C)-NLS-dCas9(C)VP64 was joined to the VEGFR1(FLT1) and VEGFR2(KDR) ectodomains . These combinations were tested in HEK293T cells and the activity of each homo- and hetero-dimer was measured  with and without transgenically expressed VEGFA121
+(Baeumler, T.A., Ahmed, A.A. and Fulga, T.A., 2017. Engineering synthetic signaling pathways with programmable dCas9-based chimeric receptors. Cell reports, 20(11), pp.2639-2653.)
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:75%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 35%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/5036/part-software/experiment-1.png
+">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
+ The graph demonstrates that the EYFP reporter, a marker of activation score, was significantly upregulated when a C-terminal dCas9 was fused to VEGFR-1 and an N-terminal dCas9 was fused to VEGFR-2 were employed in combination. This effect was particularly pronounced in the presence of VEGFA121 outperforming other dCas9-VEGFR constructs. In addition to this, the combination of VEGFR2: TEV(N)-NES-dCas9(N)/VEGFR1: TEV(C)-NLS-dCas9(C)VP64 heterodimer shows very low activation score in absence of VEGFA121
+.   </span></p></div></html>
+It was hypothesized that by fine-tuning the TCS modules, the assembly of dCas9-VP64 could be controlled so that it only occurs upon simultaneous activation of VEGFR1 and VEGFR2. To investigate this, a set of dCas9(N)-synVEGFR2 and dCas9(C)-synVEGFR1 variants with TCS sequences that had been engineered to weaken their interaction with TEV were designed.Then These combinations were tested in HEK293T cells and the activity of different dCas9-VEGFR variants with TCS sequences was measured  with and without transgenically expressed VEGFA121
+(Baeumler, T.A., Ahmed, A.A. and Fulga, T.A., 2017. Engineering synthetic signaling pathways with programmable dCas9-based chimeric receptors. Cell reports, 20(11), pp.2639-2653.)
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:75%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 35%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/5036/part-software/experiment-2.png
+">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
+ Among the tested dCas9-VEGFR constructs, a combination of dCas9-VEGFR2 with a low-affinity TCS(QL) and dCas9-VEGFR1 with a high-affinity TCS(QG) exhibited relatively low basal activity in absence of VEGFA 121 while preserving high activation score in comparison to other constructs in presence of VEGFA 121.  In other words, the previous combination shows  the most specific activation of the EYFP reporter in response to VEGFA 121
+.   </span></p></div></html>
+A HEK293 cell line was engineered to express the VEGFR2: TEV(N)-NES-dCas9(N)/VEGFR1: TEV(C)-NLS-dCas9(C)VP64 heterodimer. To assess the effectiveness of the system, flow cytometry was used to compare EYFP reporter expression in cells transfected with either a control sgRNA or one targeting EYFP.
+(Baeumler, T.A., Ahmed, A.A. and Fulga, T.A., 2017. Engineering synthetic signaling pathways with programmable dCas9-based chimeric receptors. Cell reports, 20(11), pp.2639-2653.)
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:75%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 35%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/5036/parts-experiment/receptor-3.png
+">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
+ Flow cytometry analysis of cells expressing dCas9-VEGFR constructs with either a control sgRNA (sgSCR) or a targeting sgRNA (sgEYFP) revealed that the receptor configuration treated with the targeting sgRNA was unresponsive to activation without VEGFA121 but exhibited a strong response to VEGFA121, with up to a 1,000-fold increase in EYFP activation
+.   </span></p></div></html>
+dCas9-VP64-GAL4 expression vector and a UAS-CMV trans-enhancer were constructed to investigate the effectiveness of the GAL4-UAS system for CRISPR-assisted trans-enhancer activation . Both linear (LUAS-CMV) and circular (CUAS-CMV) forms of the UAS-CMV enhancer were successfully recruited to target genes by the dCas9-VP64-fused GAL4 protein.When co-transfected with a reporter gene in 293T cells, both LUAS-CMV and CUAS-CMV significantly activated gene expression on opposite of control conditions.
+(Xu X, Gao J, Dai W, Wang D, Wu J, Wang J. Gene activation by a CRISPR-assisted trans enhancer. Elife. 2019 Apr 11;8:e45973. doi: 10.7554/eLife.45973. PMID: 30973327; PMCID: PMC6478495.)
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:75%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 35%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/5036/parts-experiment/tf-1.png
+">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
+ This figure show  Flow cytometry analysis of ZsGreen expression shows very high gene expression with (dCas9-VP64-GAL4/sgRNA-LUAS-CMV) and (dCas9-VP64-GAL4/sgRNA- CUAS-CMV)
+.   </span></p></div></html>
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:75%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 35%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/5036/parts-experiment/tf-2.png
+">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
+ This figure shows  graphic illustration of  flow cytometry analysis of  293 T cells which shows high gene expression with  both LUAS-CMV and CUAS-CMV. These findings highlight the potential of the GAL4-UAS system for efficient CRISPR-mediated trans-enhancer activation
+.   </span></p></div></html>
+Also these vectors ( dCas9-VP64-GAL4 with linear (LUAS-CMV) and circular (CUAS-CMV) CMV enhancer) were constructed and co-transfected with a reporter gene(HNF4α gene)  in HepG2 cells . then results were illustrated and compared with the results of the same construcrts in 293T cells.
+(Xu X, Gao J, Dai W, Wang D, Wu J, Wang J. Gene activation by a CRISPR-assisted trans enhancer. Elife. 2019 Apr 11;8:e45973. doi: 10.7554/eLife.45973. PMID: 30973327; PMCID: PMC6478495.)
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:75%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 35%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/5036/parts-experiment/tf-3.png
+">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
+ This figure shows graphic illustration of flow cytometry analysis of  293 T cells and HepG2 cells which shows high gene expression with (dCas9-VP64-GAL4/sgRNA-LUAS-CMV) and (dCas9-VP64-GAL4/sgRNA- CUAS-CMV). Gene expression was higher in HepG2 cells. These findings highlight the potential of the GAL4-UAS system for efficient CRISPR-mediated trans-enhancer activation
+.   </span></p></div></html>
+We have done DNA gel electrophoresis to validate the cloning of  GFP and gRNA into dCas9(C)_NLS-Syn-VEGFR-1
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:75%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 45%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/5036/lab/no.png
+">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='font-size:11.0pt;line-height:115%'>This figure illustrates the amplified fragments of our inserts GFP within P1 and gRNA shown in p5.
+.   </span></p></div></html>
+The final ligated form of plasmid dCas9(C)_NLS-Syn-VEGFR-1 was transformed into competent BL 21
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:80%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 40%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/5036/lab/yes.png
+">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='font-size:11.0pt;line-height:115%'>This figure illustrates transformation of dCas9(C)_NLS-Syn-VEGFR-1 and dCas9(N)_NES-Syn-VEGFR-2 plasmids to BL21 competent cells
+.   </span></p></div></html>
 ==Reference==
@@ Line 210: / Line 365: @@
 Morita S, Horii T, Kimura M, Hatada I. Synergistic Upregulation of Target Genes by TET1 and VP64 in the dCas9-SunTag Platform. Int J Mol Sci. 2020 Feb 25;21(5):1574. doi: 10.3390/ijms21051574. PMID: 32106616; PMCID: PMC7084704.
-Xu X, Gao J, Dai W, Wang D, Wu J, Wang J. Gene activation by a CRISPR-assisted trans enhancer. Elife. 2019 Apr 11;8:e45973. doi: 10.7554/eLife.45973. PMID: 30973327; PMCID: PMC6478495.
 <!-- Add more about the biology of this part here